Cantor Fitzgerald Downgrades Sucampo Pharmaceuticals To Hold

Cantor Fitzgerald downgraded Sucampo Pharmaceuticals, Inc. SCMP from Buy to Hold. The price target for Sucampo Pharmaceuticals is set to $18. Sucampo Pharmaceuticals shares have gained 155.09 percent over the past 52 weeks, while the S&P 500 index has surged 10.90 percent in the same period. Sucampo Pharmaceuticals' shares climbed 2.91 percent to close at $18.06 yesterday.